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Objectives: Few studies have evaluated the impact of risk factors and comorbidity on overall 
survival (OS) in patients with pancreatic ductal adenocarcinoma (PDAC). The aim was to 
investigate the prognostic importance of Charlson’s age-comorbidity index (CACI) and other risk 
factors on prognosis in a clinical real-world cohort of PDAC patients. 
 
Methods: 1159 patients with PDAC who had received at least one cycle of adjuvant or palliative 
chemotherapy were included from the Danish BIOPAC study. We analyzed OS according to CACI, 
tobacco smoking, alcohol intake, performance status (PS), BMI, and diabetes. Hazard ratios (HRs) 
and 95% confidence intervals (CIs) were estimated for OS using Cox proportional hazards 
regression.  
 
Results: At the end of follow-up 994 (86%) patients had died. The median OS was 298 days for all 
patients (range 3–3010) and shortest in patients with stage IV. No association with short OS was 
seen for CACI > 2, diabetes, alcohol abuse, tobacco smoking, hypertension, and high BMI. 
Multivariate analysis showed that stage (IV vs. I: HR=9.05, 95% CI 5.17-15.84), PS (2 vs. 0: 
HR=3.67, 2.92-4.61) and treatment with angiotensin-converting-enzyme inhibitors (yes vs. no: 
HR=1.31, 1.06-1.61) were independent negative prognostic factors.  
 
Conclusions: We found that CACI, diabetes, tobacco smoking, alcohol abuse, hypertension, and 
high BMI were not associated with OS in a real-world cohort of patients with PDAC treated with 
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Introduction 
 
Pancreatic cancer (PC) is one of the most lethal cancers worldwide (Ryan et al. 2014; Hidalgo 
2010). It is ranked as the fourth leading cancer related cause of death and the incidence is rising in 
more developed countries (Siegel et al. 2019; Ferlay et al. 2015). In 2030 PC is expected to be the 
second leading cause of death of cancer in United States (Rahib et al. 2014). Most patients with PC 
are diagnosed with advanced stage and the 5-year survival is just 7% (Pancreatic Cancer Treatment 
NCBI, NIH 2018). The causes of PC are not fully elucidated, but 5-10% of all PC cases have a 
genetic predisposition (Roberts et al. 2016; Shindo et al. 2017). The strongest evidence of a 
causative role exists only for tobacco use with a 2-fold increase of PC risk (Bosetti et al. 2012), and 
cigarette smoking is associated with poor prognosis (Yuan et al. 2017). Type 2 diabetes mellitus 
(T2DM) is a potential risk factor for PC (Batabyal et al. 2014), but its association with survival is 
equivocal (Yuan et al. 2015; Jeon et al. 2018). Obesity, chronic pancreatitis, high alcohol intake and 
blood type A, B or AB are suggested as risk factors for PC (Aune et al. 2012; Larsson et al. 2007; 
Michaud et al. 2001; Arslan et al. 2010; Duell et al. 2012; Wolpin et al. 2010; Lucenteforte et al. 
2012; Wang et al. 2016), but their impact on prognosis is unclear (Kasenda et al. 2014; Yuan et al. 
2013; Olson et al. 2010; Zhang et al. 2017; Rizzato et al. 2013; Rahbari et al. 2012). 
 
A group of experts has recommended that age, sex, disease stage, performance status (PS), liver 
metastases, previous chemotherapy or radiotherapy and previous surgery should be included in 
future studies of patients with PC to ensure better comparison of outcomes across 
hospitals/countries (Veer et al. 2018).  
 
PC affects older patients and the median age at diagnosis is 70 years (Howlader et al. 2016). Fit 
older patients with PC have the same benefits from curative surgery and combination chemotherapy 
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Many patients with PC have comorbidities, e.g. gallbladder diseases, gastric or duodenal ulcers, 
pernicious anemia, hypertension, and thyroid diseases, however the association with risk of PC is 
not clear (Olson 2012; Ko et al. 2007). Specific multi-morbidities such as ≥ 2 gastric conditions 
(heartburn, acid regurgitation, Helicobacter pylori infection, ulcer) and ≥ 3 recently diagnosed 
metabolic syndrome conditions (obesity, T2DM, hypercholesterolemia, hypertension), as well as 
combining T2DM with gastric morbidity are associated with the risk of PC (Gomez-Rubio et al. 
2017). The prognostic value of these comorbidities is poorly understood, but better PS is associated 
with longer OS (Vickers et al. 2012; Tas et al. 2013). 
 
Charlson’s Age-Comorbidity Index (CACI) measure the relative mortality from various 
comorbidities (Charlson et al. 1987; Charlson et al. 1994). Precautions exist when using scoring to 
control for comorbidities including missing weighting for particular comorbidities as well as 
uncertainty in regard to comprehensiveness of the conditions (Elixhauser et al. 1998). Higher CACI 
is associated with poorer OS in resected PC patients and patients with unresectable locally advanced 
PC treated with intra-operative radiotherapy (Asano et al. 2017; Dias-Santos et al. 2015; Cai et al. 
2013). There are no studies addressing specifically the prognostic value of CACI and its interplay 
with other risk factors in a real-world cohort of PC patients undergoing adjuvant or palliative 
chemotherapy. 
 
Given the morbidity related to chemotherapy and surgery, tools for identifying the fit PC patients 
for therapy would be of great clinical value. The aim of this study was to investigate the influence 




























This article is protected by copyright. All rights reserved 
Materials and Methods 
 
The Danish BIOPAC Study “BIOmarkers in patients with Pancreatic Cancer (BIOPAC) – can they 
provide new information of the disease and improve diagnosis and prognosis of the patients?” 
(ClinicalTrials.gov ID: NCT03311776; www.herlevhospital.dk/BIOPAC/) was initiated in July 
2008 with the aim of conducting translational biomarker research. The BIOPAC study is an open 
cohort study. All referred patients with diagnosis of PC are eligible for inclusion. The patients 
included in the BIOPAC study are followed from time of diagnosis and during treatment and 
follow-up until death. Relevant clinical characteristics of the patients are included in the BIOPAC 
database. The BIOPAC study protocol is approved by the Danish Ethics Committee (VEK, j.nr. 
KA-20060113) and the Danish Data Protection Agency (j.nr. 2012-58-0004, HGH-2015-027, I-
Suite j.nr. 03960). All patients had received oral and written information before enrolment and gave 
written consent at baseline according to the guidelines of the Danish Ethics Committee. 
 
BIOPAC is a prospective multi-center biomarker study in which biological samples (blood and 
cancer tissue) and clinical data are collected prospectively in Danish patients with localised, locally 
advanced or metastatic PC treated at seven oncological departments and one surgical department in 
Denmark. 
 
In the present study all patients were >18 years of age and had histologically verified pancreatic 
ductal adenocarcinoma (PDAC). The patients were either operated (patients with stage I and II) or 
treated with palliative chemotherapy (patients with stage III and IV) according to national 
guidelines (www.gicancer.dk). The following baseline characteristics were selected from the 
BIOPAC database: date of inclusion in the BIOPAC study (1-21 days after PDAC diagnosis), date 
of death, age, gender, diagnosis, disease stage, PS, body mass index (BMI), use of prescription 
drugs, smoking status and alcohol intake, Charlson’s comorbidity index (CCI), other previous types 
of cancer, diabetes, hypertension, family history of PC or other cancer, blood type, date of operation 
and date of first series of adjuvant chemotherapy or 1. line palliative chemotherapy (gemcitabine, 
nab-paclitaxel + gemcitabine, FOLFIRINOX, capecitabine + gemcitabine, or oxaliplatin + 
capecitabine). The patients had received at least one cycle chemotherapy. 
 
Definition of covariates 
 




]), BMI < 18.5 was 
classified as underweight, 18.5 to 25 as normal weight and > 25 as overweight; DM included 
patients with type I or type II treated with anti-diabetics, including oral medication and insulin; 
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years (Charlson et al. 1987; Charlson et al. 1994); tobacco smoking (ever smokers); alcohol abuse 
(defined as >7 units per week for women and >14 units per week for men); hypertension (i.e. 






OS was calculated as the time elapsed between the time of histologic diagnosis and the date of 
death or the date of last follow-up. Time to death was illustrated with Kaplan-Meier curves. Cox 
proportional hazard regression was used for univariate and multivariate analyses. Results were 
summarized by hazard ratios (HRs) and 95% confidence intervals (CIs). In the main analysis only 
complete cases were used. In a sensitivity analysis the substantive model compatible fully 
conditional specification multiple imputation approach proposed by Bartlett (Bartlett et al. 2015) 
was used to address the issue with missing values.  P-values less than 5% were considered as 
statistically significant. All analyses were done in R version 3.4.1. 
Results 
 
Demographics of the population 
 
1641 patients were included in the BIOPAC study from July 2008 to July 2017. 1272 patients had 
PDAC, 75 had ampullary cancer, 41 had intraductal papillary mucinous neoplasm (IPMN), 40 had 
chronic pancreatitis, 95 had other upper gastrointestinal cancer, 18 had neuroendocrine tumor and 
100 had other benign lesions. 123 of the patients with PDAC were excluded from the present study 
since they did not receive any treatment (n=51), their stage was unknown (n=41) or CACI could not 
be calculated (n=21). Therefore 1159 patients (median age 67 years, range 37 – 89 years) with 
PDAC were included in our analysis (Fig. 1). Their demographic data, including risk factors, are 
shown in Table 1. 406 (35%) patients had stage I or II disease, 187 (16%) had stage III and 566 
(49%) had stage IV. 446 (34%) were >69 years old, 424 (36%) had PS 0, 335 (29%) were 
overweight, 294 (25%) had diabetes, 448 (38%) had CACI <3, 708 (61%) were present or earlier 
tobacco smokers, 248 (22%) had an alcohol consumption higher than the recommendations, and 
409 (35%) had hypertension.  
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At the end of follow-up 994 (86%) patients had died. The median survival was 298 days (95% CI 
272-325) for all patients, 676 days (95% CI 592-783) for stage I+II, 309 days (95% CI 262-347) for 
stage III, and 185 days (95% CI 169-204) for patients with stage IV. 
 
Survival curves (all patients or divided into stages) according to age and PS (Figure 2), BMI and 
diabetes (Figure 3), CACI and hypertension (Figure 4) demonstrated that age, PS, CACI and 
hypertension had impact on OS for all patients. Only PS had impact on OS in the different stage 
groups. CACI had impact on OS for stage III and IV and hypertension for stage I+II and IV. 
 
Survival curves (all patients or divided into stages) according to sex, CCI, tobacco smoking, alcohol 
abuse, use of ACE-inhibitors, and blood type (Supplement Figures 1-6) showed that only tobacco 
smoking and treatment with ACE-inhibitors were associated with short OS for stage I-II. 
Table 2 shows univariate analysis of association between the clinical characteristics and OS. Higher 
age (>69 vs. <50 years: HR=1.50, 95% CI 1.07- 2.09), higher stage (Stage IV vs. I: HR=8.31, 5.02-
13.75; III vs. I: HR=5.14, 3.06-8.60; and II vs. I: HR=2.12, 1.28-3.51), higher PS (PS 2+ vs. 0: 
HR=3.11, 2.53-3.81; 1 vs. 0: HR=1.56, 1.36-1.80), tobacco smoking (HR=1.17, 1.01-1.34), CACI 
score (3-5 vs. 0: HR=1.60, 1.10-2.34; and >5 vs. 0: HR=1.83, 1.17-2.88), CCI (>1 vs. 0: HR=1.29,  
1.10-1.52), hypertension (yes vs. no: HR=1.23, 1.08-1.40), and treatment with ACE inhibitors 
(HR=1.25, 1.04-1.50) were all associated with shorter OS. Diabetes, blood type, and excessive 
alcohol drinking and high BMI were not significantly associated with shorter OS. 
 
Multivariate analyses including the significant parameters with either CCI or CACI, respectively, 
are presented in Table 2. Stage (Stage IV vs. I: HR=9.17, 95% CI 5.24-16.07; III vs. I: HR=5.17,  
2.92-9.18; and II vs. I: HR=1.99, 1.13-3.49), poorer PS (>2 vs. 0: HR=3.66, 2.91-4.60; 1 vs. 0: 
HR=1.50, 1.29-1.75) and treatment with ACE inhibitors (HR=1.27, 1.03-1.58) were associated with 
OS in the multivariate analysis with CACI. Similar results were found if CCI were included in the 
multivariate analysis. Age, tobacco smoking and CACI/CCI were not significant in the multivariate 
analysis. 
 
Since some of the variables had missing values (PS 10%, BMI 4%, diabetes 1%, tobacco use 9%, 
alcohol abuse 8%, hypertension 6% and blood type 19%) we considered multiple imputations by 
means of “substantive model for multiple imputation of covariates by fully conditional 
specification” (Bartlett et al. 2015). The results showed no substantial difference from the complete 
case analysis (Table 3). 
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208 (18%) of the PDAC patients had a previous history of other cancer before PDAC diagnosis. 
The most common types were breast (20%), colorectal (12%), prostate (11%), uterus (5%) and 
ovarian cancer (4%). 29% of the PDAC patients had a known family cancer disposition; the most 
common were PC (13%), colorectal (21%), breast (21%) and lung cancer (17%) (Supplement 
Figure 7).  
Discussion 
 
This population-based study demonstrated that high CACI, diabetes, tobacco smoking, alcohol 
abuse, hypertension, and high BMI have no independent prognostic impact on mortality in a large 
real-world cohort of PDAC patients treated with adjuvant or palliative chemotherapy. Our results 
confirmed that advanced stage and poor PS have significant negative effects on mortality. These 
data indicate that older PDAC patients or those with significant comorbidity should not 
automatically be excluded from surgery or chemotherapeutic treatment. 
 
Comorbidities are common in cancer patients and the prevalence increases with age. CACI, which 
combines age and comorbidity, is the most used index in longitudinal studies for estimating relative 
risk of death from prognostic clinical covariates (Charlson et al. 1987). The use of comorbidity 
indices is under discussion for cancer patients with low survival rates such as PDAC. Therefore, 
new prognostic scales should be developed for such patient groups also taking into account the 
toxicity of chemotherapy (Kos et al. 2014). CACI was useful in predicting outcome after 
pancreatectomy in 497 patients with PDAC (Dias-Santos et al. 2015). A CACI score >4 was 
predictive for increased duration of hospitalization and risk of postoperative complications, and a 3-
fold higher risk of death within the first year was found i  patients with a CACI score ≥6. In 379 
patients who underwent resection for PC the CACI score was an independent prognostic factor for 
short- and long-term outcome and patients with CACI <4 had better compliance for postoperative 
adjuvant chemotherapy than patients with CACI ≥4 (Asano et al. 2017). In 194 patients with locally 
advanced PDAC treated with intraoperative radiotherapy combined with chemotherapy a CACI of 
≤3 and treatment with chemotherapy predicted improved OS (Cai et al. 2013). 
Our results are in accordance with previous studies demonstrating that pretreatment PS is an 
independent prognostic factor for survival for patients with PDAC across all stages (Vickers et al. 
2012; Tas et al. 2013). 
 
BMI is associated with increased risk of developing PC (Aune et al. 2012; Larsson et al. 2007; 
Michaud et al. 2001; Arslan et al. 2010). However, few studies with conflicting results have 
evaluated the impact of BMI on survival of PC patients (Kasenda et al. 2014; Yuan et al. 2013; 
Olson et al. 2010). Limited information on weight loss and its influence is a possible reason for 
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patients (Piccirillo et al. 2004). Preclinical studies have shown that renin-angiotensin system 
inhibitors, including ACE inhibition decrease tumor growth and tumor-associated angiogenesis, and 
inhibit metastasis in various cancer types (Ager et al. 2008). Despite biologically plausible 
mechanisms, epidemiological studies in this area have shown limited and inconsistent results 
(Mandilaras et al. 2017; Song et al. 2017). Our results showed a significant independent negative 
impact of treatment with ACE inhibitors on OS in PDAC patients. 
 
We did not find independent impact on OS for differences in age in our population. Thus, advanced 
age should not preclude patients from receiving surgery or chemotherapy, and treatment decisions 
should be based on the physiological rather than the chronological age. 
 
Diabetes was not associated with poor OS in our study. Others have shown that PC patients with 
long-term diabetes (>4 years) had decreased survival compared with those without diabetes, 
whereas short-term diabetes was not associated with reduced survival, demonstrating a relationship 
between persistent glucose intolerance, chronic inflammation and aggressiveness (Yuan et al. 
2015). However, results are not consistent (Jeon et al. 2018) and here is a need for more detailed 
studies addressing the different impact of long-term and recent-onset diabetes, respectively on OS 
in patients with PC patients. 
Our study has limitations which should be recognized. First, our study was retrospective. Second, 
although most data were generated prospectively in the medical records, review and re-
categorization of unstructured data might introduce bias due to the differences in the accuracy or 
completeness of the recollections retrieved from the patient files. Potential mistakes during data 
collections and dialing errors into our multicenter database cannot be excluded, although our 
records were thoroughly quality-checked by two separate authors. Furthermore, we did not have the 
possibility to distinguish between IDDM and NIDDM, but it is likely that most of the patients had 
T2DM. Dietary information and past medical conditions, like chronic pancreatitis could affect the 
mortality of PDAC patients, were not considered here due to incomplete information. Another 
limitation is that the analysis did not include the type of chemotherapy used and we cannot rule out 
that our findings may have been influenced in part by differences in chemotherapy. Despite these 
limitations the current clinical real-world cohort of 1159 patients with PDAC treated in the period 
2008 to 2017 with chemotherapy is, to the best of our knowledge, the only nationwide multicenter 
based population study on consecutive PDAC patients to describe the association of CACI and 
other risk factors with mortality. 
In summary, we showed that CACI, diabetes, tobacco smoking, alcohol abuse, and BMI had no 
significant prognostic effect on mortality in PDAC patients treated with chemotherapy in routine 
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mortality in patients with PDAC. These are clinically relevant findings as regards to the 
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Table 1. Clinical characteristics of the 1159 patients with PDAC. 
 
Abbreviations: HR, hazard ratio; CI, confidence interval; PS, performance status; CACI, Charlson’s Age-Comorbidity 
Index; CCI, Charlson’s Comorbidity Index. 
 
PDAC patients     Stage      
           
Covariates  All   I – II  III   IV   
       
N  1159 406 (35) 187 (16) 566 (49)  
         
Sex (%) Female 531 (46) 193 (48) 88 (47) 250 (44)  
 Male 628 (54) 213 (52) 99 (53) 316 (56)  
         
Age (%) <50 47 (4) 19 (5) 8 (4) 20 (3)  
        
 50 – 69 666 (58) 248 (61) 103 (55) 315 (56)  
         
 >69 446 (38) 139 (34) 76 (41) 231 (41)  
          
Median (range)  67 (37 – 89) 69 (40 – 88) 67 (38 – 88) 66 (37 – 89)  
         
PS (%) 0 424 (36) 164 (41) 61 (32) 199 (35)  
         
 1 486 (42) 122 (30) 93 (50) 271 (48)  
           
 >1 137 (12) 30 (7) 24 (13) 83 (15)  
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BMI (%) <18.5 63 (6) 21 (5) 10 (5) 32 (5)  
        
 18.5 – 25 708 (61) 252 (62) 124 (67) 332 (59)  
         
 >25 335 (29) 112 (28) 45 (24) 179 (32)  
         
 Unknown 53 (4) 22 (5) 8 (4) 23 (4)  
        
Diabetes (%) No 854 (74) 291 (71) 135 (72) 428 (76)  
         
 Yes 294 (25) 113 (28) 51 (27) 130 (23)  
       
 Unknown 11 (1) 2 (1) 1 (1) 8 (1)  
         
CACI (%) 0 36 (3) 17 (4) 7 (4) 12 (3)  
         
 1-2 412 (35) 152 (38) 55 (30) 205 (36)  
        
 3 – 5 643 (56) 215 (53) 113 (60) 315 (55)  
          
 >6 66 (6) 22 (5) 12 (6) 32 (5)  
       
 Unknown 2 (0) 0 (0) 0 (0) 2 (1)  
         
CCI (%) 0 602 (52) 215 (53) 98 (53) 289 (51)  
         
 1 325 (28) 119 (30) 51 (27) 155 (27)  
          
 >1 232 (20) 72 (17) 38 (20) 122 (22)  
         
Tobacco (%) No 347 (30) 139 (34) 51 (27) 157 (28)  
        
 Yes 708 (61) 239 (59) 117 (63) 352 (62)  
           
 Unknown 104 (9) 28 (7) 19 (10) 57 (10)  
        
Alcohol abuse (%) No 806 (70) 295 (73) 131 (70) 380 (67)  
          
 Yes 248 (22) 82 (20) 38 (20) 128 (23)  
           
 Unknown 105 (8) 29 (7) 18 (10) 58 (10)  
        
Hypertension (%) No 683 (59) 238 (58) 122 (65) 323 (57)  
         
 Yes 409 (35) 148 (37) 52 (28) 209 (37)  
          
 Unknown 67 (6) 20 (5) 13 (7) 34 (6)  
         
Blood Type (%) Type 0 317 (27) 120 (30) 59 (31) 138 (24)  
         
 Other 625 (54) 239 (59) 88 (47) 298 (53)  
          
 Unknown 217 (19) 47 (11) 40 (22) 130 (23)  
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Table 2. Univariate and multivariate analysis for OS according to risk factors. 
 
 Univariate analysis            Multivariate analysis          
                               
               with CCI     with CACI    
                               
            p–        p–         p–  
 Covariates    HR   95%CI   value   HR  95%CI   value   HR   95%CI   value  
                               
 Sex Female  Ref                         
   Male 1.04  [0.92 – 1.18] 0.53                  
                          
 Age <50  Ref         Ref       Ref      
   50 – 69 1.24  [0.89 – 1.72] 0.21  1.21  [0.84 – 1.76] 0.30  1.12  [0.56 – 2.22] 0.75  
   >69 1.50  [1.07 – 2.09] 0.02  1.22  [0.83 – 1.78] 0.31  1.05  [0.52 – 2.14] 0.89  
                          
 Stage I  Ref         Ref       Ref      
   II  2.12  [1.28 – 3.51] 0.004  1.99  [1.13 – 3.49] 0.02  1.98  [1.13 – 3.49] 0.02  
   III  5.13  [3.06 – 8.60] <0.001  5.17  [2.92 – 9.18] <0.001  5.21  [2.93 – 9.24] <0.001  
   IV  8.31  [5.02 –13.75] <0.001  9.05  [5.17–15.84] <0.001  9.17  [5.24–16.07] <0.001  
                          
 PS 0  Ref         Ref       Ref      
   1 1.56  [1.36 – 1.80] <0.001  1.50  [1.29 – 1.75] <0.001  1.49  [1.28 – 1.74] <0.001  
   >1 3.11  [2.53 – 3.81] <0.001  3.67  [2.92 – 4.61] <0.001  3.66  [2.91 – 4.60] <0.001  
                             
 BMI <18.5  Ref                         
   18.5 – 25 0.82  [0.62 – 1.09] 0.17                  
   >25 0.84  [0.63 – 1.12] 0.23                  
                             
 Diabetes No  Ref                         
   Yes 1.00  [0.86 – 1.15] 0.98                  
                           
 CACI  0  Ref                 Ref      
   1-2 1.34  [0.91 – 1.98] 0.13          1.05  [0.47 – 2.35] 0.90  
   3-5 1.60  [1.10 – 2.34] 0.02          1.15  [0.50 – 2.64] 0.75  
   >6 1.83  [1.17 – 2.88] 0.009          1.37  [0.56 – 3.39] 0.49  
                            
 CCI 0  Ref         Ref               
   1 1.06  [0.92 – 1.23] 0.41  0.96  [0.82 – 1.14] 0.67          
   >1 1.29  [1.10 – 1.52] 0.002  1.07  [0.89 – 1.30] 0.47          
                          
 Tobacco No  Ref         Ref       Ref      
   Yes 1.17  [1.01 – 1.34] 0.03  1.10  [0.95 – 1.27] 0.22  1.08  [0.93 – 1.26] 0.29  
                             
 Alcohol No  Ref                         
 Abuse Yes 1.03  [0.88 – 1.20] 0.72                  
                             
 Hyper- No  Ref                         
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 ACE No  Ref                         
 Inhibitor Yes 1.25  [1.04 – 1.50] 0.016                  
                          
 Hyper- No  Ref         Ref       Ref      
 Tension Yes 1.31  [1.09 – 1.58] 0.005  1.31  [1.06 – 1.61] 0.01  1.27  [1.03 – 1.58] 0.03  
   + ACEI                           
   Yes 1.19  [1.02 – 1.38] 0.03  1.13  [0.95 – 1.34] 0.17  1.11  [0.94 – 1.32] 0.22  
   – ACEI                           
                             
 Blood Type 0  Ref                         
 Type Other 1.05  [0.91 – 1.22] 0.50                  
                               
 
Abbreviations: HR, hazard ratio; CI, confidence interval; PS, performance status; CACI, Charlson’s Age-
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Table 3. Multiple imputation analysis. 
 
Covariates  HR 95% CI p – value 
      
Age <50 Ref    
 50-69 1.21 [0.87 – 1.69] 0.26 
 >69 1.22 [0.87 – 1.72] 0.25 
      
Stage I Ref    
 II  2.11 [1.26 – 3.51] 0.00 
 III  5.09 [3.02 – 8.56] 0.00 
 IV 8.50 [5.11 – 14.11] 0.00 
      
PS 0 Ref    
 1 1.49 [1.28 – 1.73] 0.00 
 >1 3.25 [2.62 – 4.02] 0.00 
      
Tobacco No Ref    
 Yes 1.11 [0.96 – 1.28] 0.16 
      
CCI 0 Ref    
 1 0.96 [0.83 – 1.12] 1.36 
 >1 1.11 [0.93 – 1.32] 0.26 
      
Hypertension ± ACEI No Ref    
 Yes + ACEI 1.27 [1.04 – 1.55] 0.02 
 Yes – ACEI 1.13 [0.95 – 1.34] 0.18 
      
 
Abbreviations: HR, hazard ratio; CI, confidence interval; PS, performance status; CCI, Charlson’s 
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Figure Legends 
 
Figure 1. Flow diagram showing inclusion and exclusion criteria to produce the final study group.
Figure 2. Kaplan-Meier curves showing OS according to age and PS and divided into stage groups 
Figure 3. Kaplan-Meier curves showing OS according to baseline BMI and diabetes status divided 
into stage groups. 
 
Figure 4. Kaplan-Meier curves showing OS according to CACI and hypertension status and 
divided into stage groups. 
 
 




Supplement Figure 2. Kaplan-Meier curves showing OS according to CCI scoring and divided 
 
into stage groups. 
 
Supplement Figure 3. Kaplan-Meier curves showing OS according to baseline tobacco smoking 
status and divided into stage groups. 
 
Supplement Figure 4. Kaplan-Meier curves showing OS according to baseline alcohol status and 
 
divided into stage groups. 
 
Supplement Figure 5. Kaplan-Meier curves showing OS according to treatment with ACE
inhibitors and divided into stage groups. 
 





Supplement Figure 7. Flowchart showing previous history of cancer (7a) and family disposition to 
cancer (7b)  
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